USPTO Art Unit 1671 Prosecution Statistics

Art Unit Information

Art Unit: 1671
Group: 1670
Tech Center: 1600
Total Cases: 9,444
Last Active: February 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19053808Mutated Glycoprotein of Vesicular Stomatitis VirusFebruary 2025July 2025Allow510NoNo
19053784Mutated Glycoprotein of Vesicular Stomatitis VirusFebruary 2025July 2025Allow510NoNo
19017356MUTANTS OF RESPIRATORY SYNCYTIAL VIRUS FUSION PROTEINSJanuary 2025May 2025Allow410YesNo
19012978VIRAL VECTOR DELIVERY SYSTEM FOR BOTH RESPIRATORY AND DIGESTIVE TRACTS OF PIGS AND APPLICATION THEREOFJanuary 2025June 2025Allow510YesNo
19007447METHODS OF TARGETED DELIVERY TO A HOST USING A CARRIERDecember 2024May 2025Allow500NoNo
19000472BETACORONA VIRUS mRNA VACCINESDecember 2024June 2025Allow620YesNo
18964018Alpha-herpesvirus Insensitive Monoclonal Cell Strain, and Preparation Method Therefor and Use ThereofNovember 2024April 2025Allow411NoNo
18955940PREPARATION METHOD AND APPLICATION OF NANOBODY TARGETING DENGUE VIRUS NS1 PROTEINNovember 2024April 2025Allow510NoNo
18865515FUSION PROTEIN AND USE THEREOFNovember 2024March 2025Allow400NoNo
18941809NUCLEIC ACID VACCINE AGAINST THE SARS-COV-2 CORONAVIRUSNovember 2024May 2025Allow611YesNo
18936852METHODS OF FABRICATING CARRIERS FOR TARGETED DELIVERY TO A HOSTNovember 2024April 2025Allow510NoNo
18915537ENGINEERED MUSCLE TARGETING COMPOSITIONSOctober 2024May 2025Allow701NoNo
18903289METHOD FOR CONSTRUCTING gE PROTEIN-DELETED PSEUDORABIES VIRUS STRAIN USING ADENINE BASE EDITOR AND USE THEREOFOctober 2024April 2025Allow710NoNo
18801895ESTABLISHMENT AND SUSPENSION ACCLIMATION OF CRFK ADHERENT CELL LINE, AND ITS APPLICATIONAugust 2024January 2025Allow510NoNo
18801071NUCLEIC ACID VACCINESAugust 2024June 2025Abandon1010YesNo
18800440RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINEAugust 2024December 2024Allow410NoNo
18801143NUCLEIC ACID VACCINESAugust 2024January 2025Allow510NoNo
18801174NUCLEIC ACID VACCINESAugust 2024March 2025Allow710NoNo
18798779RSV RNA MOLECULES AND COMPOSITIONS FOR VACCINATIONAugust 2024May 2025Allow910NoNo
18792611COXSACKIEVIRUS B4 STRAIN AND APPLICATION THEREOFAugust 2024May 2025Abandon1010NoNo
18790657CAPSID VARIANTS AND METHODS OF USING THE SAMEJuly 2024April 2025Allow810NoNo
18788938CAPSID VARIANTS AND METHODS OF USING THE SAMEJuly 2024April 2025Allow810NoNo
18779961PREFUSION-STABILIZED HMPV F PROTEINSJuly 2024January 2025Allow610NoNo
18777836C-BASED SINGLE DOMAIN ANTIBODY FOR NEUTRALIZING RESPIRATORY SYNCYTIAL VIRUS AND APPLICATION THEREOFJuly 2024April 2025Allow910NoNo
18770056POLYNUCLEOTIDE MOLECULES USED FOR THE PREVENTION OR TREATMENT OF HPV INFECTION RELATED DISEASESJuly 2024March 2025Allow811YesNo
18762296BETACORONAVIRUS mRNA VACCINESJuly 2024October 2024Allow310YesNo
18762372BETACORONAVIRUS RNA VACCINESJuly 2024December 2024Allow510NoNo
18762384BETACORONAVIRUS RNA VACCINESJuly 2024October 2024Allow320YesNo
18751599BACTERIOPHAGE COMPOSITIONS AND METHODS FOR TREATMENT OF BACTERIAL INFECTIONSJune 2024December 2024Allow610YesNo
18749700COMPOSITIONS AND METHODS FOR AMPLIFYING, DETECTING OR QUANTIFYING HUMAN POLYOMAVIRUS BK VIRUSJune 2024April 2025Allow1001YesNo
18742986METHODS AND PRODUCTS FOR GENETIC ENGINEERINGJune 2024March 2025Allow910YesNo
18738696VACCINE MOLECULESJune 2024June 2025Allow1310NoNo
18734010ADOPTIVE CELLULAR THERAPYJune 2024May 2025Allow1210NoNo
18734520MONOCLONAL ANTIBODIES DIRECTED AGAINST TRIMERIC FORMS OF THE HIV-1 ENVELOPE GLYCOPROTEIN WITH BROAD AND POTENT NEUTRALIZING ACTIVITYJune 2024January 2025Allow800NoNo
18680187COMPOSITIONS AND METHODS FOR ENHANCING PRODUCTION, GROWTH, SPREAD, OR ONCOLYTIC AND IMMUNOTHERAPEUTIC EFFICACY OF INTERFERON-SENSITIVE VIRUSESMay 2024May 2025Allow1100YesNo
18731059METHOD OF ASSESSING RISK OF PMLMay 2024April 2025Allow1110NoNo
18680137METHODS AND CONSTRUCTS FOR PRODUCTION OF LENTIVIRAL VECTORMay 2024March 2025Allow1010NoNo
18675059CHIKUNGUNYA VIRUS (CHIKV) VIRUS-LIKE PARTICLES (VLPS) COMPRISING THE C, E1, AND E2 STRUCTURAL PROTEINSMay 2024December 2024Allow700NoNo
18668571USE AND TREATMENT OF DI-AMINO ACID REPEAT-CONTAINING PROTEINS ASSOCIATED WITH ALSMay 2024March 2025Allow1000NoNo
18665920Compositions and Methods for Antigen Targeting to CD180May 2024March 2025Allow1010NoNo
18662554METHODS FOR CONTINUOUSLY INACTIVATING A VIRUS DURING MANUFACTURE OF A PROTEINMay 2024April 2025Allow1110NoNo
18662436CHIMERIC INFLUENZA VACCINESMay 2024July 2024Allow200NoNo
18660609PORCINE EPIDEMIC DIARRHEA VIRUS STRAINS AND IMMUNOGENIC COMPOSITIONS THEREFROMMay 2024February 2025Allow900YesNo
18654901COXSACKIEVIRUS A6 STRAIN CVA6-KM-J33 AND USE THEREOFMay 2024September 2024Allow410NoNo
18649981METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENTApril 2024January 2025Allow810YesNo
18649467A549 HOST CELLS COMPRISING A RECOMBINANT ONCOLYTIC ADENOVIRUS WITH MODIFIED E1A CANCER-SPECIFIC PROMOTERApril 2024December 2024Allow800NoNo
18648190STABILIZED INFLUENZA HEMAGGLUTININ STEM REGION TRIMERS AND USES THEREOFApril 2024December 2024Allow700NoNo
18645942METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TESTApril 2024October 2024Allow611NoNo
18645951METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TESTApril 2024October 2024Allow611NoNo
18645961METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TESTApril 2024October 2024Allow611NoNo
18644438ANTIBIOTIC FREE TREATMENT OF MASTITISApril 2024December 2024Allow811YesNo
18641205COMPOSITIONS AND METHODS FOR THERAPEUTIC OR VACCINE DELIVERYApril 2024February 2025Allow1010NoNo
18637070COMPOSITIONS TARGETING APOPTOSIS-ASSOCIATED SPECK-LIKE PROTEIN WITH CASPASE ACTIVATION AND RECRUITMENT DOMAIN (ASC) AND METHODS OF USEApril 2024September 2024Allow501NoNo
18630996ENGINEERING AAVApril 2024May 2025Allow1310NoNo
18630437ANTIBODY NEUTRALIZING HUMAN RESPIRATORY SYNCYTIAL VIRUSApril 2024March 2025Allow1110NoNo
17270341BINDING PROTEIN OF NS1 PROTEINApril 2024February 2025Allow4720NoNo
18629504Mutated Glycoprotein of Vesicular Stomatitis VirusApril 2024January 2025Allow920NoNo
18629466Mutated Glycoprotein of Vesicular Stomatitis VirusApril 2024March 2025Allow1110YesNo
18629579Mutated Glycoprotein of Vesicular Stomatitis VirusApril 2024February 2025Allow1110YesNo
18629097Mutated Glycoprotein of Vesicular Stomatitis VirusApril 2024January 2025Allow920NoNo
18624929Adenoviral VectorApril 2024March 2025Allow1210NoNo
18622330IMMUNOGENIC COMPOSITIONS AND USES THEREOFMarch 2024June 2025Allow1410NoNo
18620192Nant COVID Vaccine Cross ReactivityMarch 2024August 2024Allow410YesNo
18615472NUCLEIC ACID VACCINE AGAINST THE SARS-COV-2 CORONAVIRUSMarch 2024November 2024Allow710NoNo
18616134RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINEMarch 2024August 2024Allow510NoNo
18614158PROTOPARVOVIRUS COMPOSITIONS COMPRISING A PROTOPARVOVIRUS VARIANT VP1 CAPSID POLYPEPTIDE AND RELATED METHODSMarch 2024March 2025Allow1211YesNo
18612698SARS-COV-2 RNA VACCINE COMPOSITIONS AND METHODS OF USEMarch 2024November 2024Allow810NoNo
18612771MULTIVALENT EPSTEIN-BARR VIRUS-LIKE PARTICLES AND USES THEREOFMarch 2024January 2025Allow1010NoNo
18611550MODIFIED VIRAL PARTICLES FOR GENE THERAPYMarch 2024June 2025Allow1510NoNo
18610681RNA VACCINES AGAINST INFECTIOUS DISEASESMarch 2024February 2025Allow1111NoNo
18597018Human Immunodeficiency Virus Neutralizing Antibodies And Methods Of Use ThereofMarch 2024June 2025Allow1511YesNo
18596426PRE-FUSION RSV F ANTIGENSMarch 2024November 2024Abandon910NoNo
18594435Multi-Epitope Vaccine for the Treatment of Alzheimer's DiseaseMarch 2024December 2024Allow900NoNo
18444033METHOD FOR KILLING HIV-INFECTED CELLS USING BCL-2 INHIBITORSFebruary 2024June 2025Allow1620NoNo
18443262METHOD FOR THE DETECTION AND QUANTIFICATION OF ADENO-ASSOCIATED VIRUSES (AAVs) USING AN AFFINITY MATRIXFebruary 2024January 2025Allow1120NoNo
18441086SYSTEMS AND PROCESSES TO SCREEN FOR SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2) OF 2019 (COVID-19)February 2024May 2025Allow1510NoNo
18440344ANTIBODIES AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF EPSTEIN BARR VIRUS INFECTIONFebruary 2024May 2025Allow1511NoNo
18438342COMPOSITIONS AND METHODS OF MRNA VACCINES AGAINST NOVEL CORONAVIRUS INFECTIONFebruary 2024December 2024Allow1011YesNo
18437608CONTRACEPTIVE VACCINE BASED ON THE SPERM-ASSOCIATED PROTEIN CATSPERFebruary 2024March 2025Allow1301YesNo
18436426COMPOSITIONS AND METHODS FOR ORGAN-PROTECTIVE EXPRESSION AND MODULATION OF CODING RIBONUCLEIC ACIDSFebruary 2024December 2024Allow1010NoNo
18435026MODIFIED CYTOMEGALOVIRUS PROTEINS AND STABILIZED COMPLEXESFebruary 2024April 2025Allow1411YesNo
18434265HEPATITIS B ANTIBODIESFebruary 2024January 2025Allow1210NoNo
18430151METHODS OF IMMUNOTHERAPYFebruary 2024December 2024Abandon1110NoNo
18292949ENHANCED EXPRESSION OF POLO-LIKE KINASE 3 (PLK3) IN HUMAN IMMUNODEFICIENCY VIRUS (HIV)-INFECTED CELLSJanuary 2024December 2024Allow1020YesNo
18418127RSV RNA VACCINESJanuary 2024June 2025Allow1710NoNo
18417613BROADLY SARS-CoV-2 NEUTRALIZING MONOCLONAL ANTIBODIES AND USES THEREOFJanuary 2024December 2024Allow1120NoNo
18414053VACCINE FOR USE IN THE PROPHYLAXIS AND/OR TREATMENT OF A DISEASEJanuary 2024November 2024Allow1000NoNo
18412674VLP Stabilized Vaccine CompositionsJanuary 2024May 2025Allow1630NoNo
18409645PREFUSION RSV F PROTEINS AND THEIR USEJanuary 2024December 2024Allow1110NoNo
18407208SYSTEM FOR DELIVERY OF INACTIVATED PATHOGENS FOR CONTACTLESS PASSIVE IMMUNIZATIONJanuary 2024January 2025Allow1221NoNo
18403182MULTIVALENT INFLUENZA NANOPARTICLE VACCINESJanuary 2024April 2025Allow1620NoNo
18402546VIRUS-INSPIRED COMPOSITIONS AND METHODS OF REDIRECTING PREEXISTING IMMUNE RESPONSES USING THE SAME FOR TREATMENT OF CANCERJanuary 2024February 2025Allow1410NoNo
18269284SOLANESOL VACCINE ADJUVANTS AND METHODS OF PREPARING SAMEJanuary 2024November 2024Allow1711NoNo
18396787Porcine Circovirus Type 3 (PCV3) Vaccines, and Production and Uses ThereofDecember 2023March 2025Allow1410NoNo
18394486RESPIRATORY SYNCYTIAL VIRUS MRNA VACCINEDecember 2023December 2024Allow1200NoNo
18394555REPLICATION-DEFICIENT MODIFIED VACCINIA ANKARA (MVA) EXPRESSING MARBURG VIRUS GLYCOPROTEIN (GP) AND MATRIX PROTEIN (VP40)December 2023March 2025Allow1510NoNo
18392463VLP-BASED BIVALENT EBOLA VACCINES AND METHODS OF MAKING AND USING SAMEDecember 2023January 2025Allow1310NoNo
18392147ARENAVIRUS MONOCLONAL ANTIBODIES AND USESDecember 2023April 2025Allow1611NoNo
18391486T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOFDecember 2023August 2024Allow810NoNo
18391325ANTIBODIES FOR SARS-COV-2 AND USES THEREOFDecember 2023March 2025Abandon1410NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1671.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
99
Examiner Affirmed
62
(62.6%)
Examiner Reversed
37
(37.4%)
Reversal Percentile
71.3%
Higher than average

What This Means

With a 37.4% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
517
Allowed After Appeal Filing
195
(37.7%)
Not Allowed After Appeal Filing
322
(62.3%)
Filing Benefit Percentile
75.3%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 37.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Strategic Recommendations

✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Art Unit 1671 - Prosecution Statistics Summary

Executive Summary

Art Unit 1671 is part of Group 1670 in Technology Center 1600. This art unit has examined 9,444 patent applications in our dataset, with an overall allowance rate of 82.5%. Applications typically reach final disposition in approximately 24 months.

Comparative Analysis

Art Unit 1671's allowance rate of 82.5% places it in the 69% percentile among all USPTO art units. This art unit has an above-average allowance rate compared to other art units.

Prosecution Patterns

Applications in Art Unit 1671 receive an average of 1.57 office actions before reaching final disposition (in the 28% percentile). The median prosecution time is 24 months (in the 76% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more favorable examination environment compared to the USPTO average.
  • With fewer office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is shorter than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.